Palvella Therapeutics, Inc.
HealthcareNASDAQ:PVLA · NASDAQ Global Market
+$2.43 today
Vol 0.36M · Avg 0.25M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-149.1%
avg -100.9%
ROIC
-79.7%
avg -130.3%
ROA
-70.0%
avg -12.2%
Analysis
ROA is currently the strongest return metric at -70.0% versus its period average of -12.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Wesley H. Kaupinen | Founder, President, Chief Executive Officer & Director | $935,018.00 | — | — | $124,603.00 | 1.05% |
Kathleen Goin | Chief Operating Officer | $673,820.00 | — | 55 | $10,781.00 | 0.09% |
Matthew E. Korenberg | CFO, Corporate Secretary & Treasurer | $665,420.00 | — | 51 | $44,123.00 | 0.37% |
Jeffrey Martini | Chief Scientific Officer | $530,435.00 | — | 48 | $64,318.00 | 0.54% |
Ashley Kline | Chief Commercial Officer | — | — | 45 | $38,517.00 | 0.33% |
Bohan Wei | Vice President of Corporate Development & New Product Planning | — | — | — | — | — |
Emily Cook | Senior Vice President of Clinical Operations | — | — | — | — | — |
Jennifer McDonough | Senior Vice President of Market Access & Patient Services | — | — | — | — | — |
Sarah Foster | Senior Vice President of Human Resources | — | — | — | — | — |
Vimal Patel | Senior VP of Medical Affairs | — | — | — | — | — |
Jason Burdette | SVP of CMC & Technical Operations | — | — | — | — | — |
Kent Taylor | Senior Vice President of Sales | — | — | — | — | — |
David W. Osborne | Chief Innovation Officer | — | — | 65 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$849,973.50
Sells
18
$3.08M
Net Sentiment
$2.23M
Net selling
Most Active
Goin Kathleen
18 transactions
1–10 of 21
Analysis
Insiders reported 3 buys worth $849,973.50 and 18 sells worth $3.08M over the last 12 months. That adds up to net selling of $2.23M. Goin Kathleen was the most active insider with 18 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
GH Research PLC
NASDAQ:GHRS
$1.45B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Savara Inc.
NASDAQ:SVRA
$1.08B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$969.20M
Arbutus Biopharma Corporation
NASDAQ:ABUS
$841.51M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages PVLA?
Palvella Therapeutics, Inc. (PVLA) lists 13 active executives. The top listed executive is Kathleen Goin, Chief Operating Officer.
Are PVLA insiders buying or selling?
Recent insider activity shows net buying of $56.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.